Inovio Pharmaceuticals (INO) Stock Statistics & Valuation Metrics

Inovio Pharmaceuticals has a market cap or net worth of $120.92M. The enterprise value is $81.29M.

Inovio Pharmaceuticals has 68,703,380 shares outstanding. The number of shares has decreased by -2.65% in one year.

Inovio Pharmaceuticals’s return on equity (ROE) is -1.57 and return on invested capital (ROIC) is -0.13%.

The current PE Ratio of Inovio Pharmaceuticals is ―. Inovio Pharmaceuticals’s PEG ratio is 0.01.

In the last 12 months, Inovio Pharmaceuticals had revenue of 217.76K and earned -107.25M in profits. Earnings per share was -3.95.

In the last 12 months, operating cash flow was -20.88B and capital expenditures -127.32K, giving a free cash flow of -20.88B billion.

Inovio Pharmaceuticals pays an annual dividend of $0.069, resulting in a dividend yield of ―

Inovio Pharmaceuticals upcoming earnings date is Mar 3, 2026, TBA (Confirmed).

Inovio Pharmaceuticals as a current ratio of 2.77, with Debt / Equity ratio of 37.36%

In the past 12 months, Inovio Pharmaceuticals has paid 0.00 in taxes.

Inovio Pharmaceuticals EV to EBITDA ratio is 0.04, with an EV/FCF ratio of 0.04.

Inovio Pharmaceuticals has $50.80M in cash and marketable securities with $10.02M in debt, giving a net cash position of $40.78M billion.

Gross margin is -1152.27%, with operating margin of -51616.91%, and net profit margin of -49254.27%.

The average price target for Inovio Pharmaceuticals is $7.33, which is 11.43% higher than the current price. The consensus rating is Moderate Buy